SEO URLwww.firestrike.ai/deals/astria-therapeutics-biocryst-acquisition-2026-1
acquisitionAnnounced · Jan 23, 2026biopharmaceuticalSource · CredibleArticle · Factual
BioCryst acquires Astria Therapeutics
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$700M
Target
Astria Therapeutics
NASDAQ: ATXS · Boston, Massachusetts
Acquirer
BioCryst
Full Acquisition
Status
Pending
BioCryst agreed to acquire Astria Therapeutics. Reported deal value: $700M. Status: Pending. Sector: biopharmaceutical. Target headquarters context: Boston, Massachusetts, United States.
This page summarizes publicly available information about the transaction as of 2026-01-23. Figures and status may change as filings and press coverage update.
BioCryst Pharmaceuticals , Inc. agreed to acquire Astria Therapeutics , Inc. from group of shareholders for approximately $7 20 million on October 14, 20 25
Deal timeline
Announced
Jan 23, 2026 · marketscreener.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biopharmaceutical with a reported deal value of $700M. Figures and status may change as sources update.
Sources: marketscreener.com · Primary article · FireStrike proprietary index